# Generated by ReviewAid
Filename,Title,Author,Year,Confidence,Reason for Inclusion
1-s2.0-S0022510X21003166-main.pdf,Wearing-off symptoms during standard and extended natalizumab dosing intervals: Experiences from the COVID-19 pandemic,Gerd Haga Bringeland,2021,0.95,"The paper studies adults (population) receiving natalizumab (intervention) with outcomes related to multiple sclerosis (MS) regarding wearing-off symptoms during standard (SID) and extended (EID) dosing intervals. It meets all inclusion criteria for population, intervention, and outcomes."
1-s2.0-S221103482100612X-main.pdf,Safety of Natalizumab infusion in multiple sclerosis patients during active SARS-CoV-2 infection,Landi D,2021,0.95,"The paper focuses on Natalizumab (intervention) in adults with Multiple Sclerosis (population) during active SARS-CoV-2 infection, which meets all inclusion criteria (population: adults; intervention: Natalizumab, SID, EID; outcomes: MS). No exclusion criteria are violated."
1-s2.0-S1878747924000370-main.pdf,Commentary Extended interval dosing of natalizumab: More evidence in support,Karlo Toljan,2024,0.95,"The paper evaluates extended interval dosing (EID) of natalizumab versus standard interval dosing (SID) in adults with multiple sclerosis (MS), assessing outcomes such as disease activity, relapse rates, and safety (including PML risk). It meets all PICO criteria: population (adults), intervention (natalizumab, SID/EID), comparison (SID vs EID), and outcomes (MS)."
10.1007@s00415-014-7574-6.pdf,LETTER TO THE EDITORS Intense immunosuppression for the treatment of an immune reconstitution inﬂammatory syndrome-like exacerbation after natalizumab withdrawal: a case report,Maria Sepu´lveda,2014,0.95,"The paper focuses on a case of immune reconstitution inflammatory syndrome (IRIS) following natalizumab withdrawal in an adult with multiple sclerosis (MS), and describes treatment with intense immunosuppression (cyclophosphamide and rituximab). This matches the population (adults), intervention (natalizumab, SID/EID), and outcomes (MS) criteria. Exclusions for ocrelizumab and fingolimod are not violated."
"A real world multi center study on efficacy and safety of natalizumab in Indian patients with multiple sclerosis_Author links open overlay panel_Thomas Mathew a_, _Vikram Kamath b_, _Saji K John a_, _M Netravat.pdf",A real world multi center study on efficacy and safety of natalizumab in Indian patients with multiple sclerosis,Thomas Mathew,2022,0.95,"The paper focuses on natalizumab (matching the intervention inclusion criteria) in adults with multiple sclerosis (matching population inclusion criteria). It reports efficacy and safety outcomes relevant to MS, with no exclusion of the intervention or population that would disqualify it."
Bernardes et al. - 2024 - Natalizumab extended interval dosing what about wearing-off effect.pdf,Natalizumab extended interval dosing: what about wearing-off effect?,Catarina Bernardes,2024,0.95,"The paper focuses on adults with Multiple Sclerosis (MS) receiving natalizumab, comparing standard interval dosing (SID) to extended interval dosing (EID) as the intervention, with outcomes related to MS (wearing-off effect). It meets all inclusion criteria for population (adults), intervention (natalizumab, SID/EID), and outcomes (MS)."
Bigaut et al. - 2021 - Long-term effect of natalizumab in patients with RRMS TYSTEN cohort.pdf,Long-term effect of natalizumab in patients with RRMS: TYSTEN cohort,Kévin Bigaut,2020,0.95,"The paper studies the long-term effect of natalizumab in adults with relapsing-remitting multiple sclerosis (RRMS), which aligns with the PICO criteria. The population includes adults (age ≥18 years), the intervention focuses on natalizumab (matching inclusion criteria for NTZ, SID, EID), and outcomes relate to MS (e.g., SPMS, EDSS progression). All specified inclusion/exclusion criteria for population, intervention, and outcomes are met."
"Bomprezzi and Pawate - 2014 - Extended interval dosing of natalizumab a two-center, 7-year experience.pdf","Extended interval dosing of natalizumab: a two-center, 7-year experience",Roberto Bomprezzi,2014,0.95,"The paper focuses on natalizumab (included intervention) in adult patients (included population) with multiple sclerosis outcomes (included), comparing standard monthly dosing to extended interval dosing (EID), which aligns with the PICO criteria."
Brandstadter et al. - 2017 - The use of natalizumab for multiple sclerosis.pdf,The use of natalizumab for multiple sclerosis,Rachel Brandstadter,2017,0.95,"The paper is a review on natalizumab for multiple sclerosis, which matches the intervention (natalizumab) and population (adults) criteria. It discusses outcomes related to MS, and there is no violation of exclusion criteria."
